PepPool: SARS-CoV-2 (S1), scanning

PepPool: SARS-CoV-2 (S1), scanning


Publications: 28
Validated for our assays.


Peptide pool with 166 peptides, 25 ug of each peptide. Supplied in two vials (lyophilized).

In stock

Delivery 4-9 business days

Shipping $0

Product specifications

Intended use

This peptide pool is intended for studying immune responses against SARS-CoV-2 (S1 domain of spike protein) using immunoassays such as ELISpot and FluoroSpot. It induces cytokine secretion from antigen-specific human T cells. For research use only. Not for use in diagnostic procedures.

Serum/Plasma samples

The SARS-CoV-2 (S1) scanning pool induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human T cells. It contains 166 peptides from the human SARS-CoV-2 virus. The peptides are 15-mers overlapping with 11 amino acids, covering the S1 domain of the spike protein (amino acid 13-685). The pool is supplied in two vials: pool 1 SARS-CoV-2 S1 peptides 1-83 (83 peptides) and pool 2 SARS-CoV-2 S1 peptides 84-166 (83 peptides). The mean purity of the synthetic peptides is 80%.

Peptides included in the peptide pool are listed in the datasheet.


Product details

ProductPepPool: SARS-CoV-2 (S1), scanning
ApplicationT cell stimulation, ELISpot, FluoroSpot, Flow cytometry
Supplied in



Peptide pool with 166 peptides, 25 ug of each peptide. Supplied in two vials (lyophilized).

Shipping and Storage


Shipped at ambient temperature.


Store at -20 °C or below upon receipt.

Human PBMC (300,000 cells/well) from a convalescent individual, previously confirmed CODID-19 positive with PCR, were incubated overnight in the absence or presence of the SARS-CoV-2 S1 scanning pool and anti-CD28 mAb and the number of cells secreting IFN-γ was analyzed by ELISpot.

Highlighted research, Published May 17, 2022

Third vaccine dose important for T cell response against Omicron
Three doses mRNA vaccine had better T cell responses than recipients of two doses. Mabtech IRIS and FluoroSpot Flex: Human IFN-γ/TNF-α/IL-2/Granzyme B were used to assess T cell immunity in mRNA vaccine recipients.
Loading publications...
1 / 3